Purpose: Evaluate the implementation of a large hospital system vancomycin dosing guideline in a community hospital with pharmacist vancomycin management. Design: Single center, retrospective and prospective quality assessment study. Methods: Pharmacist-managed vancomycin therapy was evaluated pre and post-implementation of a new dosing guideline in a study population of 586 from one community hospital. Results: Of the study population, 274 patients evaluated pre-implementation were compared to 312 patients post-implementation of the large hospital-system guideline (46.8% and 53.2%, respectively). There was no significant difference in demographics between both patient populations. Days of vancomycin therapy was shorter in the post-implementation group (4.32  2.241) versus the pre-implementation group [(4.81  2.764), p = 0.018]. Days to goal trough was longer in the post-implementation group (3.51  1.622) compared to the pre-implementation group [(3.09  2.046), p = 0.054]. A post-hoc regression analysis was conducted, showing that age, days of vancomycin therapy and goal trough are predictors for 77% of cases within the post-implementation group. Conclusion: The implementation of a new vancomycin dosing guideline significantly impacted days of vancomycin therapy and days to goal trough in patients on vancomycin managed by pharmacists. Our results encourage completion of future studies utilizing the regression analysis data, which may impact the future care of patient on vancomycin managed by pharmacists.
Introduction


Vancomycin is one of the most commonly-used antimicrobials in the treatment of gram positive infections, especially those colonized with MRSA (methicillin-resistant Staphylococcus aureus). Vancomycin's effectiveness as a bactericidal agent is dependent on its time above the MIC (minimum inhibitory concentration) [1] . Due to its complex PK (pharmacokinetic) and PD (pharmacodynamic) properties, dosing vancomycin can be challenging for clinicians.
In January 2017, TJC (The Joint Commission) mandated ASPs (antimicrobial stewardship programs) within hospitals and nursing care centers [2] . According to standard MM.09.01.01, the purpose of ASPs is to improve and measure the appropriate use of antibiotic agents. This is achieved through promoting the selection of optimal antibiotics, including dose, duration of therapy, and route of administration. Pharmacists are a critical member of the ASP multidisciplinary team, and help improve patient outcomes and reduce antibiotic adverse events [2, 3, 4] .
Vancomycin dosing and monitoring is one of many facets of ASPs. TJC recommends hospitals implement PK monitoring and adjustment programs for D DAVID PUBLISHING
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Following Implementation of a System-Wide Vancomycin Dosing Guideline 608 vancomycin [3] . In a meta-analysis of studies evaluating vancomycin dosing, hospitals with vancomycin TDM (therapeutic drug monitoring) produced more favorable outcomes of clinical efficacy than those without TDM (OR 2.62, 95% CI 1.34-5.11, p = 0.005) [5, 6] . When comparing patients on vancomycin pre and post-implementation of a pharmacist-directed pilot program, the percentage of patients who received optimal (i.e.  30 mg/kg/day within 24 h of initiation of therapy) vancomycin doses was significantly greater in the pharmacist-managed vancomycin group compared to those not managed by pharmacists (96.8% vs. 40.4%, respectively) [7] . Over 50% more patients were optimally dosed and had a shorter duration of therapy (10.0 vs. 8.4 days, p < 0.003) [7] . In addition to achieving optimal dosing, pharmacist vancomycin management provides clinical and economic benefits. In hospitals without pharmacist-managed aminoglycoside and vancomycin therapy, length of stay was 12.28% greater (131,660 excess patient days) and death rates were 6.71% higher (1,048 excess deaths) (p < 0.0001). Laboratory charges were 7.80% increased ($22,530,474 in excess charges) and total Medicare charges were 6.30% higher ($34,769,250) (p < 0.0001) compared to hospitals that have pharmacist-managed vancomycin and aminoglycoside therapy. Lastly, in hospitals lacking pharmacist management, there was an excess of $34,769,250 in drug charges [8] . Pharmacists play an important role in achieving and improving patient clinical outcomes and benefiting the health system through multiple cost-savings.
The IDSA (Infectious Diseases Society of America), ASHP (American Society of Health-System Pharmacists), and the SIDP (Society of Infectious Diseases Pharmacists) released consensus hospital recommendations for vancomycin therapeutic guidelines in 2009. Some of the recommendations were calculating initial vancomycin doses based on actual body weight, with subsequent doses administered based on serum trough concentrations. Trough concentrations are deemed the most accurate and effective method of monitoring vancomycin, and should be drawn before the fourth dose as this is approximately the time when vancomycin is at steady-state within the body [9] . Lastly, the consensus statement identifies concentration ranges to improve vancomycin penetration and clinical outcomes. In patients with more severe infections such as bacteremia, sepsis, osteomyelitis, endocarditis, meningitis and pneumonia, trough serum concentrations of 15-20 mg/L are recommended. Lower trough concentrations of 10-15 mg/L are appropriate for SSTIs (skin and soft tissue infections) and UTIs (urinary tract infections) [9] .
Following the 2009 guidelines a survey of U.S. hospitals was conducted to identify similarities and inconsistencies in vancomycin dosing. Of 163 respondents, pharmacy services were automatically consulted to dose vancomycin in 51% of the institutions [10] . Even with the consensus guidelines and pharmacist vancomycin management, actual vancomycin dosing practices are not universal among hospitals. Of the recommendations, a majority of hospitals do use trough target concentrations of 15-20 mg/L for more complicated infections. However, there is great variability in timing of trough concentrations and use of loading doses [10] .
UHSJMC (University Hospitals St. John Medical Center) is a 204-bed nonprofit teaching community hospital that provides care to patients in northeast Ohio. Since 2011, pharmacists at UHSJMC have been consulted to dose and monitor vancomycin. While utilizing the established protocol ( Fig. 1) , pharmacists have hypothesized that adjustments may be necessary in the young, renally impaired, and elderly populations. Following incorporation into UH (University Hospitals) health system in late 2015, UHSJMC adopted UH's vancomycin dosing guideline (Fig. 2) . The new vancomycin guideline provides clear, concise, and conservative dosing recommendations 
Statistical Analysis
It was determined that a sample size of 84 patients per study group (pre and post-UH guideline) was required to achieve a power of 90%. Continuous data are displayed as mean  SD (standard deviation) and were compared using the student's t test. Categorical data were evaluated using proportions and were compared using the χ 2 test. A post-hoc regression analysis was conducted to correlate study variables pre and post-UH guideline with clinical outcomes. A p value of < 0.05 was considered statistically significant.
Results and Discussion
Results
A total of 1,096 patients were reviewed for inclusion in the study with a total of 586 patients enrolled, 274 and 312 in the pre and post-UH guideline groups, respectively (Fig. 3) . A majority of patients in both groups were in the elderly age category and normal renal function category. There were no statistically significant differences in baseline demographics between the two groups ( Table 1) .
Of the 586 patients, the most common infections treated with vancomycin were SSTIs, pneumonia, and sepsis (Fig. 4) . In the pre and post-UH guideline groups, 138 (50.4%) and 148 (47.4%) of patients achieved their goal serum concentration. Of the 138 patients in the pre-UH group, 57 (41.3%) had a goal trough of 10-15 mg/L and 81 (58.7%) had a goal trough of 15-20 mg/L. The mean days to goal trough in both groups were 2.70 and 3.95 respectively. Furthermore, of the 148 patients in the post-UH group, 55 (37.2%) had a goal trough of 10-15 mg/L and 93 (62.8%) had a goal trough of 15-20 mg/L. The mean days to goal trough in this group were 3.18 and 3.74.
The mean days of vancomycin therapy were statistically reduced in the post-UH guideline group (p = 0.018) versus days to goal serum trough concentration, which was greater in the post-UH guideline group (p = 0.054) ( Table 2) .
Discussion
Previous data has proven that pharmacists play an important role in ASPs. According to vancomycin guidelines published by the IDSA, ASHP and SIDP in 2009, vancomycin should be monitored via serum trough concentrations prior to the fourth dose. Concentrations of 10-15 mg/L are recommended for UTIs and SSTIs, and concentrations of 15-20 mg/L are recommended for sepsis, osteomyelitis, meningitis, and pneumonia. In hospitals surveyed, approximately 50% have pharmacists consulted to dose vancomycin. However, with ASPs, vancomycin guidelines and pharmacist involvement, hospitals still lack universal vancomycin management [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Prior to the initiation of the UH vancomycin dosing guideline, pharmacists at UHSJMC hypothesized that adjustments may be necessary in certain populations due to differences in pharmacokinetic and pharmacodynamic characteristics. Empiric vancomycin dosing pre-UH was based on weight and goal trough concentrations, with the dosing interval based on CrCl. While the new vancomycin dosing guideline at UHSJMC is similar to the old version, there are a few differences. Empiric vancomycin dosing is solely based upon the patient weight and renal function and does not take the goal trough concentration into consideration. In the same manner as the original vancomycin guideline, the UH guideline formats its dosing frequency based on the patient's renal function, or CrCl. Both guidelines utilize the same CrCl ranges, with the UH guideline more clearly stating the recommendations for patients with intermittent HD (hemodialysis) and CRRT (continuous renal replacement therapy). There are also more dosing ranges based on weight in the new dosing guideline, which is beneficial for those patients who weigh less than 60 kg.
The following is an example of the dosing differences between the two vancomycin protocols:
JR is an 83 year old male who weighs 76kg with a CrCl = 32 mL/min. You are consulted to dose vancomycin for presumed pneumonia in JR. Based on the old vancomycin dosing guideline, JR would be prescribed vancomycin 1.5 g IV every 24 h. However, based on the new vancomycin guideline, JR would
